PYPD: צמיחת רווחי EPS רבעונית PolyPid
PolyPid Ltd. (PYPD) risks facing regulatory rejection and a funding shortage amid intensifying competition. Meanwhile, surgeons value PolyPid Ltd. for its innovative extended-release antibiotic delivery systems. Production is automated via PLEX conveyors, eliminating manual labor. The quarterly EPS growth history helps determine the asset's fundamental floor, with the latest mark standing at 55.40.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_PYPD_-_PolyPid-Ltd._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "PolyPid (PYPD): צמיחת רווחי EPS רבעונית מ-04.07.2022 עד 10.11.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור PolyPid Ltd. (PYPD)
PolyPid Ltd. is characterized by a critical dependence on FDA approval for the D-PLEX drug and a high risk of capital burn. The current value of 55.40 reflects the dynamics of net earnings per share, measuring the business's ability to generate real income amid clinical trials, which allows for an assessment of the company's resilience to shocks through the quarterly EPS growth trend and helps avoid overpaying for the asset.
